Thermo Fisher Scientific (TMO) Debt to Equity (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Debt to Equity for 18 consecutive years, with $0.83 the latest figure, recorded in Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.83, up 19.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.83 (up 19.98% YoY), and the FY2025 annual result was $0.74, up 16.82% from the prior year.
• Debt to Equity was $0.83 for Q1 2026 at Thermo Fisher Scientific, up from $0.74 in the prior quarter.
• Over five years, Debt to Equity peaked at $0.83 in Q2 2023 and troughed at $0.63 in Q4 2024.
• Average Debt to Equity over 5 years is $0.74, with a median of $0.75 recorded in 2024.
• Year-over-year, Debt to Equity jumped 52.49% in 2022 and retreated 15.54% in 2024.
• Over 5 years, Debt to Equity stood at $0.78 in 2022, then declined by 4.59% to $0.75 in 2023, then declined by 15.54% to $0.63 in 2024, then climbed by 16.82% to $0.74 in 2025, then advanced by 12.71% to $0.83 in 2026.
• Per Business Quant data, the three most recent Debt to Equity figures were $0.83 in Q1 2026, $0.74 in Q4 2025, and $0.7 in Q3 2025.